Factors Influencing Bloodstream Infections After Immunosuppressive Therapy in Patients with Aplastic Anemia: a Logistic Regression Analysis

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2024 Nov 15

PMID 39544808

Authors

Jing Li

Changqing Xue

Gang Liu

Gonggang Gao

Dahai Wei

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the risk factors for bloodstream infection after immunosuppressive therapy in patients with aplastic anemia using logistic regression.

Methods: A retrospective analysis was conducted on the clinical data from 70 patients with aplastic anemia admitted to the People's Hospital of Zitong County and the Infectious Disease Hospital in Jiangyou City from March 2011 to March 2023. Patients were divided into two groups based on whether they developed an infection after treatment: the infection group (n = 18) and the non-infection group (n = 52). Risk factors for bloodstream infection following immunosuppressive therapy were analyzed, and the predictive value of independent risk factors was assessed.

Results: Univariate analysis identified age, diabetes, disease severity, albumin levels, neutrophil count, and concurrent infections before treatment as significant risk factors for bloodstream infection following immunosuppressive therapy (all P<0.05). Multivariate analysis further confirmed that age, diabetes, disease severity, albumin levels, and neutrophil count were independent risk factors for bloodstream infection (all P<0.05). ROC curve analysis revealed that age, diabetes, disease severity, albumin levels, and neutrophil count had area under the curve (AUC) values of 0.678, 0.728, 0.698, 0.740, and 0.739, respectively, in predicting bloodstream infection after immunosuppressive therapy. The sensitivity values were 65.39%, 78.85%, 67.31%, 67.31%, and 76.92%, respectively, while the specificity values were 72.22%, 66.67%, 72.22%, 77.78%, and 61.11%, respectively.

Conclusion: Age, diabetes, disease severity, albumin levels, and neutrophil count are key factors influencing bloodstream infection after immunosuppressive therapy in patients with aplastic anemia. These findings highlight the need for careful monitoring of these factors during immunosuppressive therapy to reduce the risk of bloodstream infection.

References

Giudice V, Selleri C . Aplastic anemia: Pathophysiology. Semin Hematol. 2022; 59(1):13-20. DOI: 10.1053/j.seminhematol.2021.12.002. View

Bhargawa S, Singh A, Yadav G, Kushwaha R, Verma S, Tripathi A . Aplastic anemia severity and IL-6 and IL-8 blood levels. Discoveries (Craiova). 2023; 10(4):e157. PMC: 10362975. DOI: 10.15190/d.2022.16. View

Camp J, Glaubitz L, Filla T, Kaasch A, Fuchs F, Scarborough M . Impact of Immunosuppressive Agents on Clinical Manifestations and Outcome of Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Analysis in 2 Large, Prospectively Evaluated Cohorts. Clin Infect Dis. 2021; 73(7):1239-1247. DOI: 10.1093/cid/ciab385. View

Storb R . Allogeneic bone marrow transplantation for aplastic anemia. Int J Hematol. 2022; 119(3):220-230. PMC: 10300230. DOI: 10.1007/s12185-022-03506-6. View

Waterlow N, Cooper B, Robotham J, Knight G . Antimicrobial resistance prevalence in bloodstream infection in 29 European countries by age and sex: An observational study. PLoS Med. 2024; 21(3):e1004301. PMC: 10939247. DOI: 10.1371/journal.pmed.1004301. View

Lin H, Yang L, Fang J, Gao Y, Zhu H, Zhang S . Clinical Characteristics of Bloodstream Infection in Immunosuppressed Patients: A 5-Year Retrospective Cohort Study. Front Cell Infect Microbiol. 2022; 12:796656. PMC: 9014008. DOI: 10.3389/fcimb.2022.796656. View

Chen M, Zhuang J, Duan M, Zhang W, Li J, Zhu T . [Posaconazole as primary prevention of fungal infection in intensive immunosuppressive therapy for severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2018; 39(2):128-131. PMC: 7342574. DOI: 10.3760/cma.j.issn.0253-2727.2018.02.010. View

Abdolrasouli A, Schelenz S . Photo Quiz: Bloodstream infection in a neutropenic patient with severe aplastic anemia. J Clin Microbiol. 2023; 61(9):e0056623. PMC: 10575194. DOI: 10.1128/jcm.00566-23. View

Lee J, Kim Y, Yi N, Kim H, Lee H, Lee B . Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol. 2014; 20(2):192-203. PMC: 4099335. DOI: 10.3350/cmh.2014.20.2.192. View

10.

Uyar B . The analysis of immunosuppressant therapy adherence, depression, anxiety, and stress in kidney transplant recipients in the post-transplantation period. Transpl Immunol. 2022; 75:101686. DOI: 10.1016/j.trim.2022.101686. View

11.

Cugno C, Cesaro S . Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012; 4(1):e9. PMC: 3357622. DOI: 10.4081/pr.2012.e9. View

12.

Abdolrasouli A, Schelenz S . Answer to the Photo Quiz: Bloodstream infection in a neutropenic patient with severe aplastic anemia. J Clin Microbiol. 2023; 61(9):e0057623. PMC: 10575292. DOI: 10.1128/jcm.00576-23. View

13.

Yu W, Yang W . Interlukin-27 rs153109 polymorphism confers the susceptibility and prognosis of aplastic anemia in Chinese population. Int J Lab Hematol. 2021; 44(1):150-156. DOI: 10.1111/ijlh.13700. View

14.

Altay D, Yilmaz E, Ozcan A, Karakukcu M, Unal E, Arslan D . Hepatitis-associated aplastic anemia in pediatric patients: single center experience. Transfus Apher Sci. 2020; 59(6):102900. DOI: 10.1016/j.transci.2020.102900. View

15.

Lin H, Gao Y, Qiu Y, Du W, Zhu H, Li J . Impact of age group on bloodstream infection risk evaluation in immunosuppressed patients: a retrospective, single-centre, 5-year cohort study. Aging Clin Exp Res. 2022; 35(2):357-366. DOI: 10.1007/s40520-022-02299-2. View

16.

Kawabe S, Iwata N, Nishida E, Kohagura T, Abe N, Nakaseko H . Combination immunosuppressant therapy for rapidly progressive pyoderma gangrenosum in a child. Mod Rheumatol Case Rep. 2020; 5(1):137-140. DOI: 10.1080/24725625.2020.1749359. View

17.

Pan P, Chen C, Hong J, Gu Y . Autoimmune pathogenesis, immunosuppressive therapy and pharmacological mechanism in aplastic anemia. Int Immunopharmacol. 2023; 117:110036. DOI: 10.1016/j.intimp.2023.110036. View

18.

Biswajit H, Pratim P, Kumar S, Shilpi S, Krishna G, Aditi A . Aplastic anemia: a common hematological abnormality among peripheral pancytopenia. N Am J Med Sci. 2012; 4(9):384-8. PMC: 3456476. DOI: 10.4103/1947-2714.100980. View

19.

McNamara J, Righi E, Wright H, Hartel G, Harris P, Paterson D . Long-term morbidity and mortality following bloodstream infection: A systematic literature review. J Infect. 2018; 77(1):1-8. DOI: 10.1016/j.jinf.2018.03.005. View

20.

Coley-Grant D, Herbert M, Cornes M, Barlow I, Ford C, Gama R . The impact of change in albumin assay on reference intervals, prevalence of 'hypoalbuminaemia' and albumin prescriptions. Ann Clin Biochem. 2015; 53(Pt 1):112-6. DOI: 10.1177/0004563215599560. View